Alberta Investment Management Corp Grows Stake in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Alberta Investment Management Corp increased its stake in ADMA Biologics Inc by 17.8%, owning approximately 294,250 shares valued at around $5.8 million as of the latest SEC filing.
• Recent insider trading activity included significant sales by directors, with Steve Elms selling 194,749 shares and Lawrence P. Guiheen selling 20,000 shares, indicating a decrease in their respective ownership percentages.
• ADMA Biologics reported a quarter with earnings per share of $0.14, missing analyst expectations, while its revenue grew by 40.2% year-over-year, totaling $114.80 million.

Alberta Investment Management Corp lifted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 17.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 294,250 shares of the biotechnology company's stock after purchasing an additional 44,557 shares during the period. Alberta Investment Management Corp owned about 0.12% of ADMA Biologics worth $5,838,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ADMA. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of ADMA Biologics in the 1st quarter valued at about $35,000. Tsfg LLC bought a new position in ADMA Biologics in the first quarter worth $51,000. Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics during the first quarter worth $52,000. Farther Finance Advisors LLC raised its stake in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,505 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at $85,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ADMA shares. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th.

Insider Activity at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. The trade was a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,621 shares of company stock worth $9,644,269. 3.70% of the stock is owned by company insiders.

ADMA Biologics Trading Down 2.4%

ADMA Biologics stock traded down $0.49 during trading hours on Tuesday, hitting $19.43. The stock had a trading volume of 955,510 shares, compared to its average volume of 3,050,258. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. The stock has a market cap of $4.64 billion, a price-to-earnings ratio of 22.84 and a beta of 0.38. ADMA Biologics Inc has a one year low of $11.22 and a one year high of $25.67. The business's 50 day simple moving average is $18.81 and its 200-day simple moving average is $18.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company's revenue for the quarter was up 40.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.08 EPS. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.